观察托伐普坦治疗慢性心力衰竭合并低钠血症患者的近期疗效及安全性  

To Observe the Short-term Efficacy and Safety of Tolvaptan in the Treatment of Chronic Heart Failure with Hyponatremia

作　　者：潘琳 PAN Lin(Department of Cardiology,Chaoyang Central Hospital,Chaoyang 122000,China)

机构地区：[1]朝阳市中心医院心内科,辽宁朝阳122000

出　　处：《中国医药指南》2021年第30期95-97,共3页Guide of China Medicine

摘　　要：目的探究慢性心力衰竭合并低钠血症患者应用托伐普坦进行治疗的近期疗效和安全性。方法本次试验对象全部选自本院2018年4月至2019年5月期间收治的100例慢性心力衰竭合并低钠血症患者,根据患者的入院先后时间分成试验组(n=50)和对照组(n=50),对照组患者进行基础治疗,在此基础上试验组患者通过托伐普坦治进行治疗,分析比较两种治疗方式对患者产生的影响。结果试验组的治疗总有效率明显高于对照组,差异有统计学意义(P<0.05);两组患者的ADH、NT-proBNP、体质量、24 h尿量详情、LVEF以及血清钠水平对比,差异有统计学意义(P<0.05);两组不良反应发生率差异无统计学意义(P>0.05)。结论慢性心力衰竭合并低钠血症患者应用托伐普坦进行治疗,能够显著提升治疗效果。Objective To explore the short-term efficacy and safety of tolvaptan in the treatment of chronic heart failure with hyponatremia.Methods One hundred patients with chronic heart failure and hyponatremia admitted to our hospital from April 2018 to May 2019 were divided into experimental group(n=50)and control group(n=50)according to the time of admission.The patients in control group were treated with basic therapy.On this basis,the experimental group was treated with tolvaptan.Analyze and compare the effects of the two treatment methods on patients.Results The total effective rate of the experimental group was significantly higher than that of the control group(P<0.05);ADH,NT-proBNP,body mass,24 hour urine volume details,LVEF and serum sodium levels of the two groups were significantly different(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Tolvaptan can significantly improve the therapeutic effect in patients with chronic heart failure and hyponatremia.

关 键 词：托伐普坦 慢性心力衰竭 低钠血症 近期疗效 安全性 

分 类 号：R541.6[医药卫生—心血管疾病]